Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MORAGA, Calif., June 17, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced the completion of a $4.5 million Series A-1 financing. The financing round was led by existing Chilean-based investor Aurus, through its Aurus Bios Fund, and is supplemented by a grant awarded by the government of Chile. Proceeds for the Series A-1 round will be used to fund the completion of the Phase II TRIG-05 clinical trial evaluating the Company’s lead drug candidate, TI-001, an intranasal oxytocin therapy, for the treatment of chronic migraine.
Help employers find you! Check out all the jobs and post your resume.
